Spots Global Cancer Trial Database for stage ii multiple myeloma
Every month we try and update this database with for stage ii multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00482495 | Multiple Myelom... | bevacizumab gene expression... protein express... laboratory biom... | 18 Years - | Mayo Clinic | |
| Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00006890 | Multiple Myelom... | prednisone thalidomide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | NCT00024466 | Multiple Myelom... | GVAX Autologous tran... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | NCT00482846 | Mucositis Multiple Myelom... | Palifermin melphalan questionnaire a... autologous peri... quality-of-life... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma | NCT00005987 | Multiple Myelom... | carmustine cyclophosphamid... dexamethasone etoposide filgrastim mitoxantrone hy... recombinant int... sargramostim bone marrow abl... peripheral bloo... radiation thera... | - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | NCT00243035 | Refractory Mult... Stage II Multip... Stage III Multi... | bortezomib tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Interleukin-12 in Treating Patients With Multiple Myeloma | NCT00003149 | Multiple Myelom... | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00075881 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | NCT00064038 | Multiple Myelom... Plasma Cell Neo... | dexamethasone lenalidomide placebo | 18 Years - | SWOG Cancer Research Network | |
| Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00729118 | Multiple Myelom... Plasma Cell Neo... | lenalidomide vorinostat | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide | NCT00899080 | Multiple Myelom... | gene expression... reverse transcr... immunoenzyme te... laboratory biom... platelet aggreg... | - 120 Years | Eastern Cooperative Oncology Group | |
| S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00040937 | Multiple Myelom... | filgrastim sargramostim cyclophosphamid... dexamethasone melphalan prednisone thalidomide peripheral bloo... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
| CI-994 in Treating Patients With Advanced Myeloma | NCT00005624 | Multiple Myelom... | CI-994 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | NCT00012350 | Multiple Myelom... | FTI | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma | NCT00566098 | Multiple Myelom... | MILs Melphalan PCV13 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | NCT00118170 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | sorafenib tosyl... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00075881 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004165 | Multiple Myelom... | filgrastim melphalan peripheral bloo... | - | Northwestern University | |
| Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma | NCT00028886 | Multiple Myelom... | filgrastim recombinant int... cyclophosphamid... dexamethasone doxorubicin hyd... melphalan thalidomide vincristine sul... bone marrow abl... peripheral bloo... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00478075 | Multiple Myelom... | bortezomib immunologic tec... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma | NCT00400686 | Anemia Multiple Myelom... Plasma Cell Neo... | epoetin alfa | 18 Years - | The Cleveland Clinic | |
| Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00742404 | Multiple Myelom... | bortezomib dexamethasone pegylated lipos... protein analysi... immunologic tec... | 18 Years - | National Cancer Institute (NCI) | |
| Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | NCT00006244 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | melphalan recombinant int... aldesleukin in vitro-treate... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma | NCT00008242 | Multiple Myelom... | dexamethasone doxorubicin hyd... thalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment | NCT00389701 | Multiple Myelom... | bortezomib dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma | NCT00003195 | Multiple Myelom... | recombinant int... busulfan allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Beta Alethine in Treating Patients With Myeloma | NCT00006466 | Multiple Myelom... Precancerous Co... | beta alethine | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma | NCT01074060 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim cyclophosphamid... autologous hema... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma | NCT00005834 | Multiple Myelom... | filgrastim cisplatin cyclophosphamid... dexamethasone etoposide thalidomide | 18 Years - | SWOG Cancer Research Network | |
| Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00568880 | Multiple Myelom... | bortezomib hydroxychloroqu... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | NCT00012350 | Multiple Myelom... | FTI | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | NCT00064038 | Multiple Myelom... Plasma Cell Neo... | dexamethasone lenalidomide placebo | 18 Years - | SWOG Cancer Research Network | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma | NCT00335647 | Multiple Myelom... | fluphenazine hy... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | NCT00334932 | Multiple Myelom... | bortezomib melphalan pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | NCT00398515 | Refractory Mult... Stage II Multip... Stage III Multi... | lenalidomide temsirolimus pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | NCT00248430 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... | aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | NCT00998049 | Multiple Myelom... Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim | 18 Years - | Mayo Clinic | |
| Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | NCT00118170 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac... | sorafenib tosyl... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | NCT00743288 | Multiple Myelom... | Melphalan Panobinostat | 18 Years - | Oncotherapeutics | |
| Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00008229 | Multiple Myelom... | filgrastim melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma | NCT00014339 | Multiple Myelom... | Wobe-Mugos E melphalan prednisone quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | NCT00002989 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | busulfan cyclophosphamid... idarubicin melphalan radiation thera... | 16 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma | NCT00004088 | Multiple Myelom... | filgrastim recombinant int... busulfan cyclophosphamid... melphalan pamidronate dis... thalidomide peripheral bloo... | - 65 Years | City of Hope Medical Center | |
| Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma | NCT00112879 | Stage I Multipl... Stage II Multip... Stage III Multi... Refractory Plas... | arsenic trioxid... ascorbic acid dexamethasone thalidomide anti-cytokine t... antiangiogenesi... biological ther... chemotherapy drug resistance... growth factor a... non-specific im... | 18 Years - | National Cancer Institute (NCI) | |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | NCT00064038 | Multiple Myelom... Plasma Cell Neo... | dexamethasone lenalidomide placebo | 18 Years - | SWOG Cancer Research Network | |
| Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00445484 | Multiple Myelom... | pneumococcal po... lenalidomide | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | NCT00002556 | Stage I Multipl... Stage II Multip... Stage III Multi... | vincristine sul... carmustine melphalan cyclophosphamid... prednisone recombinant int... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00045136 | Multiple Myelom... | melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma | NCT00499577 | Multiple Myelom... | CMV pp65 peptid... hTERT I540/R572... pneumococcal po... survivin Sur1M2... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00477750 | Multiple Myelom... | lenalidomide melphalan prednisone | 18 Years - | Mayo Clinic | |
| High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | NCT01534143 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | pharmacological... tacrolimus sirolimus anti-thymocyte ... fludarabine pho... busulfan bortezomib allogeneic hema... laboratory biom... | 18 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00941720 | Multiple Myelom... | busulfan cyclophosphamid... autologous hema... | 18 Years - | Case Comprehensive Cancer Center | |
| Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients | NCT01653106 | Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | cryotherapy questionnaire a... pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | NCT00522392 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | NCT00998049 | Multiple Myelom... Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | plerixafor filgrastim | 18 Years - | Mayo Clinic | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00941720 | Multiple Myelom... | busulfan cyclophosphamid... autologous hema... | 18 Years - | Case Comprehensive Cancer Center | |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01055301 | Multiple Myelom... Plasma Cell Mye... | bortezomib cisplatin cyclophosphamid... dexamethasone doxorubicin hyd... etoposide lenalidomide melphalan thalidomide gene expression... microarray anal... laboratory biom... autologous-auto... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain | NCT00482378 | Multiple Myelom... Pain | Pamidronate Zoledronic acid Sm 153 lexidron... | 18 Years - 120 Years | Mayo Clinic | |
| Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | NCT01057225 | Multiple Myelom... Stage I Multipl... Stage II Multip... Stage III Multi... | carfilzomib cyclophosphamid... thalidomide dexamethasone | 18 Years - | Mayo Clinic | |
| Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure | NCT00416897 | Multiple Myelom... Renal Failure | chemotherapy dexamethasone plasmapheresis | 18 Years - | National Cancer Institute (NCI) | |
| O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma | NCT00004072 | Multiple Myelom... | O6-benzylguanin... carmustine | - | Case Comprehensive Cancer Center | |
| Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | NCT00602706 | Multiple Myelom... | sargramostim melphalan autologous hema... peripheral bloo... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00477750 | Multiple Myelom... | lenalidomide melphalan prednisone | 18 Years - | Mayo Clinic | |
| Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00008229 | Multiple Myelom... | filgrastim melphalan peripheral bloo... holmium Ho 166 ... | 18 Years - 70 Years | Fred Hutchinson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
